Review
doi: 10.1111/j.1600-079X.2007.00451.x.
Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment
Affiliations
- PMID: 17614829
- DOI: 10.1111/j.1600-079X.2007.00451.x
Item in Clipboard
Review
Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment
J Pineal Res.
2007 Aug.
Abstract
Prostate cancer is a public health problem of the elderly men. It has been estimated that one in six men will develop prostate cancer in his lifetime in the USA. There is thus a huge clinical demand for effective therapies for the prevention and treatment of the disease. Here, the scientific evidence supporting the effectiveness of melatonin in inhibiting the development and progression of prostate cancer is reviewed. The rational use of melatonin in prostate cancer prevention, stabilization of clinically localized favourable-risk prostate cancer and palliative treatment of advanced or metastatic tumour is discussed within the context of the molecular pathogenesis of the disease.
Comment in
-
Melatonin as an adjuvant to therapeutic prostate cancer vaccines.J Pineal Res. 2008 Sep;45(2):224. doi: 10.1111/j.1600-079X.2008.00563.x. Epub 2008 Jan 21. J Pineal Res. 2008. PMID: 18221313 No abstract available.
Similar articles
-
Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention.J Pineal Res. 2007 Mar;42(2):191-202. doi: 10.1111/j.1600-079X.2006.00406.x. J Pineal Res. 2007. PMID: 17286752
-
Review of recent evidence in support of a role for statins in the prevention of prostate cancer.Curr Opin Urol. 2008 May;18(3):333-9. doi: 10.1097/MOU.0b013e3282f9b3cc. Curr Opin Urol. 2008. PMID: 18382245 Review.
-
Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro.J Pineal Res. 2008 Oct;45(3):258-70. doi: 10.1111/j.1600-079X.2008.00585.x. Epub 2008 Apr 2. J Pineal Res. 2008. PMID: 18384530
-
Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States).Cancer Causes Control. 2005 Oct;16(8):901-15. doi: 10.1007/s10552-005-2367-y. Cancer Causes Control. 2005. PMID: 16132800 Review.
-
Pharmacological approaches to reducing the risk of prostate cancer.Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. Eur Urol. 2009. PMID: 19200641 Review.
Cited by
-
Co-delivery of Siape1 and Melatonin by 125I-loaded PSMA-targeted Nanoparticles for the Treatment of Prostate Cancer.Recent Pat Anticancer Drug Discov. 2024;19(4):503-515. doi: 10.2174/1574892818666230419081414. Recent Pat Anticancer Drug Discov. 2024. PMID: 39044710 Free PMC article.
-
Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study.Br J Cancer. 2008 Jul 8;99(1):176-8. doi: 10.1038/sj.bjc.6604425. Epub 2008 Jun 10. Br J Cancer. 2008. PMID: 18542076 Free PMC article.
-
Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones.Free Radic Biol Med. 2009 Jan 15;46(2):253-62. doi: 10.1016/j.freeradbiomed.2008.10.029. Epub 2008 Nov 1. Free Radic Biol Med. 2009. PMID: 18996184 Free PMC article.
-
Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors.In Vivo. 2017 Sep-Oct;31(5):801-809. doi: 10.21873/invivo.11133. In Vivo. 2017. PMID: 28882945 Free PMC article.
-
Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells.Asian J Androl. 2009 Nov;11(6):653-61. doi: 10.1038/aja.2009.56. Epub 2009 Sep 21. Asian J Androl. 2009. PMID: 19767760 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
